BioE to Participate in Launch of International Research Consortium on Cord Blood and Adult Stem Cells for Therapuetic Applications.BioE's Gayl Chrysler to serve on stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. commercialization panel at launch of Novussanguis in Paris ST. PAUL St. Paul as a missionary he fearlessly confronts the “perils of waters, of robbers, in the city, in the wilderness.” [N.T.: II Cor. 11:26] See : Bravery , Minn. -- BioE([R]), Inc., a biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. company that provides enabling, high-quality human stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young for drug discovery and therapeutic research, announced today Gayl Chrysler, vice president of cellular technologies and clinical affairs for BioE, will participate in the launch of Novussanguis, an international research consortium on cord blood cord blood n. Blood present in the umbilical vessels at the time of delivery. and adult stem cells for therapeutic applications, in Paris, France on Wed., May 14. To be unveiled at the Medical School of University Paris Descartes, the Novussanguis consortium will consist of approximately 15 regenerative medicine and cell therapy laboratories around the world. Novussanguis was co-founded by BioE research collaborator Professor Colin McGuckin and his team at Newcastle University (Great Britain Great Britain, officially United Kingdom of Great Britain and Northern Ireland, constitutional monarchy (2005 est. pop. 60,441,000), 94,226 sq mi (244,044 sq km), on the British Isles, off W Europe. The country is often referred to simply as Britain. ) and the Foundation Jerome Lejeune in Paris. BioE's Chrysler was invited to the Novussanguis launch to serve on a panel about innovation, commercialization and patentability of regenerative medicine and cell therapy given BioE's experience commercializing its cord blood stem cell, the Multi-Lineage Progenitor Cell progenitor cell See stem cell. [TM] (MLPC MLPC Marxist-Leninist Party of Canada MLPC Midwest Lakes Policy Center (Madison, Wisconsin) MLPC Movement for the Liberation of the Central African People (Central African Republic) [TM]). "It is an honor to support the efforts of Novussanguis," Chrysler said. "This research consortium has the potential to collaboratively identify workable stem cell solutions for treating a wide variety of diseases and conditions. In the ever-evolving field of stem cell research, more transparent and coordinated research is what is going to advance the science quicker and ultimately improve the lives of patients." During the past three years, more than 100 academic research institutions, corporate laboratories and pharmaceutical organizations globally have licensed the MLPC from BioE for stem cell and regenerative medicine research purposes. BioE also is engaged in collaborative stem cell research partnerships to further understand the potential therapeutic applications of the MLPC. Novussanguis' launch announcement is available on BioE's Web site at www.bioe.com. About BioE Headquartered in St. Paul, Minn., BioE is a biomedical company that provides enabling cord blood stem cell tools and technologies. The company's proprietary PrepaCyte([R])-CB Processing System easily and efficiently separates stem cells from cord blood for cryopreservation cryopreservation /cryo·pres·er·va·tion/ (-prez?er-va´shun) maintenance of the viability of excised tissue or organs by storing at very low temperatures. cry·o·pres·er·va·tion n. and eventual transplantation in humans. BioE's clonal, cord blood-derived Multi-Lineage Progenitor Cell([TM]) (MLPC([TM])) stem cell -- isolated using the company's PrepaCyte cell separation platform -- can differentiate into multiple cell types and lineages and is readily available to clinicians and researchers for therapeutic research and drug discovery. BioE is privately owned and was founded in 1993. For more information about the company, please visit www.bioe.com or call (800) 350-6466. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion